Literature DB >> 2536475

Hormone-negative, chromogranin A-positive endocrine tumors.

R E Sobol1, V Memoli, L J Deftos.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536475     DOI: 10.1056/NEJM198902163200707

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  21 in total

Review 1.  Human pituitary adenomas. Recent advances in morphological studies.

Authors:  G Giannattasio; M Bassetti
Journal:  J Endocrinol Invest       Date:  1990-05       Impact factor: 4.256

2.  Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer.

Authors:  Songnan Qi; Mo Huang; Huan Teng; Yudong Lu; Min Jiang; Lin Wang; Jinfang Shi; Qing Ma; Guohao Gu; Yinqiang Xin; Hongwei Ma
Journal:  Tumour Biol       Date:  2015-07-18

3.  Solid-cystic tumour of the pancreas. An endocrine neoplasm?

Authors:  A von Herbay; B Sieg; H F Otto
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

Review 4.  The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors.

Authors:  P Rosa; H H Gerdes
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

5.  Immunocytochemical localization of prohormone convertase 1/3 and 2 in gastrointestinal carcinoids.

Authors:  T Tomita
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  A Calcitonin Non-producing Neuroendocrine Tumor of the Thyroid Gland.

Authors:  Atsuko Kasajima; José Cameselle-Teijeiro; Lourdes Loidi; Yoshio Takahashi; Noriaki Nakashima; Satoko Sato; Fumiyoshi Fujishima; Mika Watanabe; Tadao Nakazawa; Hiroshi Naganuma; Tetsuo Kondo; Ryohei Kato; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

7.  The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth.

Authors:  F Jockenhövel; S Lederbogen; T Olbricht; H Schmidt-Gayk; E P Krenning; S W Lamberts; D Reinwein
Journal:  Clin Investig       Date:  1994-01

8.  In vivo imaging of chromogranin A-positive endocrine tumours by three-step monoclonal antibody targeting.

Authors:  A G Siccardi; G Paganelli; A E Pontiroli; M Pelagi; P Magnani; G Viale; G Faglia; F Fazio
Journal:  Eur J Nucl Med       Date:  1996-11

9.  Chromogranin A and B gene expression in carcinomas of the breast. Correlation of immunocytochemical, immunoblot, and hybridization analyses.

Authors:  A Pagani; M Papotti; H Höfler; R Weiler; H Winkler; G Bussolati
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

10.  Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract.

Authors:  G Schürmann; U Raeth; B Wiedenmann; H Buhr; C Herfarth
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.